J. S. Salmon

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

T. Dang, R. Herbst, D. Carbone, 2010, Lung cancer.

Non-Hodgkin's Lymphoma Involving the Liver: Clinical and Therapeutic Consideration

J. Greer, R. Arildsen, M. Thompson, 2006 .

Non-Hodgkin's lymphoma involving the liver: clinical and therapeutic considerations.

J. Greer, R. Arildsen, M. Thompson, 2006, Clinical lymphoma & myeloma.

Anti-Angiogenic Treatment of Gastrointestinal Malignancies

J. Berlin, A. Lockhart, J. S. Salmon, 2005, Cancer investigation.

MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC)

D. D. Billheimer, T. Dang, R. Herbst, 2005 .

A Complete Pathological Response to Pembrolizumab following ex vivo Liver Resection in a Patient with Colorectal Liver Metastases

D. Levi, M. Kamionek, D. Vrochides, 2018, Chemotherapy.